Enzymatica insiders plan to subscribe for SEK 16 million in new issue
03 May 2016 - 6:08PM
Enzymatica announces that
insiders such as board members, senior executives and their family
members plan to subscribe for shares in the ongoing new issue
equivalent to an amount of at least SEK 16 million, which
corresponds to 27 percent of the issue. The rights issue is set to
raise approximately SEK 60 million for the company before issue
expenses. The rights issue is 100% underwritten via subscription
and underwriting commitments.
As previously announced by the company, the main
terms and conditions of the rights issue are as follows:
The company's shareholders will have preemptive
rights to subscribe for the new shares in proportion to the number
of shares they previously held. One (1) subscription right will be
received for each existing share. Five (5) subscription rights
entitle the holder to subscribe for three (3) new shares. The
subscription price will be SEK 2.18 for each new share. For more
information, please see
http://enzymatica.com/investors/nyemission-april-2016
Schedule:
April
21-May 3 |
Trading
in subscription rights |
April
21-May 6 |
Subscription period |
May
11 |
Estimated
date of publication of rights issue outcome |
The proceeds of the rights issue will be used to
finance the company's geographic expansion, cover the costs of
product development, including clinical studies and product
documentation, and conduct its operating activities.
For
more information, contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:
fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica AB is a life sciences company that develops and sells
medical devices for fighting infectious diseases. In a short period
of time, the company developed ColdZyme®, a unique mouth spray for
fighting colds, launched the product in six markets and established
it as one of the best-selling cold products in Swedish pharmacies
measured in SEK. Our strategy is to continue growing by
strengthening our position on existing markets and expanding to
more geographic markets via established partners. The company's
head office is in Lund and it is listed on the Nasdaq First North.
For more information, please go to: www.enzymatica.se.
Enzymatica's certified advisor is Erik Penser
Bankaktiebolag.
Press Release (PDF)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
HUG#2009264
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Enzymotec Ltd. - Ordinary Shares (delisted) (NASDAQ): 0 recent articles
More Enzymatica AB News Articles